-
Sino Biopharm’s Subsidiary invoX Restructures, Focusing on CD137/PD-L1 Molecule FS222
•
UK-based biotechnology company invoX, an international subsidiary established by China-based Sino Biopharmaceutical Group in 2021, is reportedly undergoing a strategic downsizing. The company is focusing its efforts on its lead candidate, the CD137/PD-L1 bispecific molecule FS222, while reducing its workforce. According to Endpoints News, which cited a direct email from…
-
Sino Biopharmaceutical’s Subsidiary invoX Completes Additional Investment in pHion Therapeutics
•
The UK-based invoX Pharma Ltd, a wholly-owned subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177), has revealed the completion of a second tranche of investment in the Belfast-based company pHion Therapeutics. Specific details regarding the first or second tranche of investment and invoX’s current stake-holding in pHion have not been…
-
Sino Biopharmaceutical’s F-star Therapeutics Signs Second Licensing Deal with Takeda
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a second licensing agreement between its recently acquired subsidiary, F-star Therapeutics Inc. (NASDAQ: FSTX), and Japan-based Takeda Pharmaceutical Co., Ltd (TYO: 4502). The deal provides Takeda with a next-generation tumor immunotherapy bispecific antibody (BsAb), with the specific target or other molecule details undisclosed.…
-
F-star Therapeutics’ Acquisition by invoX Pharma Cleared by CFIUS
•
UK biotech F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that it has received clearance from the Committee on Foreign Investment in the United States (CFIUS) for the all-cash acquisition by invoX Pharma Limited, a UK-based subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177). This clearance is a significant step towards…
